

Supplementary Table 1. Comparison of clinical parameters between the patients with and without diabetic retinopathy

Variable	Total	DR (-)	Any DR (+)	P value
Number	523	288	235	
Mean HbA1c during follow-up, %	8.2±1.2	8.0±0.9	8.5±1.1	0.005
<6.5	16 (3.1)	14 (4.9)	2 (0.9)	
<7.0	70 (13.4)	54 (18.8)	16 (6.8)	
7.0 to <8.0	171 (32.7)	111 (38.5)	60 (25.5)	
8.0 to <9.0	146 (27.9)	83 (28.8)	63 (26.8)	
9.0 to <10.0	95 (18.2)	34 (11.8)	61 (26.0)	
≥10.0	41 (7.8)	6 (2.1)	35 (14.9)	
Mean total cholesterol, mmol/L	4.59±0.57	4.59±0.55	4.60±0.59	0.759
Mean TG, mmol/L	1.67±0.81	1.70±0.94	1.64±0.61	0.346
Mean HDL-C, mmol/L	1.13±0.21	1.13±0.22	1.13±0.21	0.868
Mean LDL-C, mmol/L	2.66±0.52	2.63±0.52	2.70±0.51	0.160
<2.6	227 (43.4)	135 (46.9)	92 (39.1)	
2.6 to <3.3	253 (48.4)	130 (45.1)	123 (52.3)	
≥3.3	43 (8.2)	23 (8.0)	20 (8.5)	
Mean TG/HDL-C	1.6±1.0	1.6±1.1	1.5±0.7	0.435
Mean non-HDL-C	3.5±0.6	3.4±0.6	3.4±0.4	0.964
Insulin use during the study ^a	190 (35.6)	63 (21.9)	121 (51.5)	<0.001
ACEi/ARB use during the study ^a	243 (45.6)	130 (45.1)	106 (45.1)	0.994
Aspirin use during the study ^a	75 (14.1)	45 (15.6)	29 (12.3)	0.284
Statin use during the study ^a	144 (27.0)	86 (29.9)	56 (23.8)	0.123
Fenofibrate use during the study ^a	43 (8.1)	24 (8.3)	19 (8.1)	0.918

Values are presented as mean ± standard deviation or number (%).

DR, diabetic retinopathy; HbA1c, glycosylated hemoglobin; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

^aMedication utilization in this table was defined prescription over 75% of total period during the follow-up.